Topics:

Taxotere Approved in Canada for Advanced Breast Cancer and NSCLC

Taxotere Approved in Canada for Advanced Breast Cancer and NSCLC

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) has received approval from the Canadian Health Protection Branch for use as second-line treatment of advanced breast and non-small-cell lung cancer (NSCLC). The new drug submission was based on clinical trials involving more than 800 patients worldwide.

 
Loading comments...
Please Wait 20 seconds or click here to close